Latest news with #OncoAssure
Irish Post
29-04-2025
- Business
- Irish Post
Irish medtech firm develops ‘powerful new tool' for cancer management
AN IRISH medtech firm has developed a new prostate cancer test which has been described as a 'powerful new tool' for managing the disease. Dublin-headquartered OncoAssure revealed their Novel Prostate Cancer Prognostic Test at the American Urological Association's (AUA) 2025 annual meeting in Nevada, Las Vegas this week. It is now available on the US market, allowing clinicians to offer improved personalised prostate cancer management services. The prognostic test designed to 'support clinical decision-making for men diagnosed with localised prostate cancer' the firm explained. Des O'Leary, CEO and co-founder of OncoAssure, pictured at NovaUCD in Dublin, (Pic: Vincent Hoban, UCD) 'The novel test helps assess the risk of aggressive disease and disease recurrence and can be used at two key decision points in the prostate cancer pathway, post-biopsy and post-surgery,' they added. 'By integrating advanced genomic insights with clinical data, OncoAssure Prostate provides a more accurate assessment of disease prognosis, empowering physicians, along with their patients, to make more precise and personalized treatment decisions.' OncoAssure CEO Des O'Leary said the launch represents a "major milestone in the commercialisation of the test in the US market'. 'Access to prognostic testing remains limited for many patients in the US, making the launch of OncoAssure Prostate especially timely,' he added. 'This test addresses a critical need by providing reliable information to distinguish between aggressive and low-risk forms of prostate cancer, helping to reduce overtreatment and improve patient outcomes.' Mr O'Leary further revealed that the firm is now focusing on developing their next product - a prognostic test for skin melanoma. Founded by Mr O'Leary and Professor William Gallagher in 2021, OncoAssure is headquartered at NovaUCD. See More: Dublin, Nevada, NovaUCD, OncoAssure, Prostate Cancer, US
Irish Independent
29-04-2025
- Business
- Irish Independent
Irish start-ups recognised globally for work in sustainability and medtech
EcoVerify, a company that verifies and trains small businesses on sustainability and their carbon footprint, has become the first organisation in the world that can verify the carbon neutrality claims of businesses. Laura Mora, managing director at EcoVerify, said the accreditation will help Ireland take the lead in climate action and transparency. 'In a world of shifting regulations and rising ESG (environmental, social, and governance) scrutiny, verified sustainability is no longer optional – it's a strategic differentiator,' Ms Mora said. 'Sustainability isn't just for the big players. SMEs verified today are tomorrow's preferred suppliers. We are therefore delighted to achieve the certification which ensures that the confidence in the quality of services we offer to the market is fully justified.' Set up in 2023, EcoVerify has worked with SMEs to help them comply with global sustainability standards. The firm was granted ISO 14068-1, which outlines the various requirements for achieving carbon neutrality, by the Dutch Accreditation Council. EcoVerify is also the first Irish-owned firm accredited under ISO 17029, which allows it to verify carbon neutrality and net-zero credentials. It said that the new accreditation will allow the company expand its services to include tailored training and verification programmes for small businesses to strengthen their work around sustainability. Irish medtech company OncoAssure has said it will launch its new diagnostic tool for prostate cancer into the US market. The test is designed to help professionals assess cancer risk in their patients. It can be used to make key decisions in the treatment of cancer, post-biopsy and post-surgery. ADVERTISEMENT Learn more OncoAssure, co-founded by Des O'Leary and Professor William Gallagher in 2021, made the announcement at the American Urological Association's (AUA) annual meeting in Las Vegas. 'This launch represents a major milestone in the commercialisation of the test in the US market,' said Mr O'Leary, who is the firm's CEO. 'Access to prognostic testing remains limited for many patients in the US, making the launch of OncoAssure Prostate especially timely. 'This test addresses a critical need by providing reliable information to distinguish between aggressive and low-risk forms of prostate cancer, helping to reduce overtreatment and improve patient outcomes.' The company, headquartered at University College Dublin's research hub NovaUCD, will hold an investment round later this year to fund the commercialisation and continued development of its products. Mr O'Leary said the prostate test works by identifying genes that show the progression of cancer. He said it would be easy for medical professionals to integrate it into their work. 'The OncoAssure prostate test incorporates the widely used CAPRA (Cancer of the Prostate Risk Assessment) score – a way for doctors to evaluate cancer risk – allowing seamless integration into current care pathways,' he said. He added that it would help the company introduce more cancer detection products 'Building on this momentum, we've made strong progress in developing our next product, a prognostic test for skin melanoma,' he said.
